Work

Supplemental Table 3 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Year: 2023

Type: supplementary-materials

Abstract: Bortezomib pharmacokinetic parameters following a single intravenous 1.3 mg/m2 bolus dose in the presence or absence of tabalumab and dexamethasone

DOI: 10.1158/1078-0432.22467206

Authors: Noopur S. Raje, Edward A. Faber, Paul G. Richardson, Gary Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher J. Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362402978

Cites:

Cited by:

Related to: 10